TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26428409

Group type: EXPERIMENTAL
Intervention: Palifermin, 60 μg/kg, intravenously as a single dose 3 days before and 0, +1, and +2 post autologous HSCT infusion
Number of subjects: 0
Study: 25056465

Group type: EXPERIMENTAL
Intervention: 60° mediolateral episiotomy
Number of subjects: 330

Group type: COMPARATOR
Intervention: 40° mediolateral episiotomy
Number of subjects: 330
Study: 22382148

Group type: EXPERIMENTAL
Intervention: CD4(+)CD38(+)HLADR(+)%, CD4(+)CD38(‐)HLADR(+)%, CD8(+)CD38(+)HLADR(+)%; measured in relation to full-scale Intelligence Quotient scores (FSIQ)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: CD4(+)CD38(+)HLADR(‐)%
Number of subjects: 126
Study: 19462314

Group type: EXPERIMENTAL
Intervention: Candesartan-HCT combination therapy (candesartan 2-32 mg and HCT 6.25-25 mg)
Number of subjects: 4632

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4632
Study: 17459238

Group type: EXPERIMENTAL
Intervention: 1CU accommodative intraocular lens
Number of subjects: 54

Group type: COMPARATOR
Intervention: Array multifocal intraocular lens
Number of subjects: 54
Study: 15919302

Group type: EXPERIMENTAL
Intervention: SaphLITE vein harvest (SVH)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Conventional open vein harvest (OVH)
Number of subjects: 225
Study: 11226654

Group type: EXPERIMENTAL
Intervention: New technique for burn depth measurement based on histological assessment of dermal microvascular occlusion
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: New technique for burn depth measurement
Number of subjects: 5
Study: 10072988

Group type: EXPERIMENTAL
Intervention: qi-gong therapy (group b: 12 GYSK cases, group c: 19 YXYK cases)
Number of subjects: 45

Group type: COMPARATOR
Intervention: nifedipine therapy (group d)
Number of subjects: 45
Study: 8420857

Group type: EXPERIMENTAL
Intervention: Iced injectate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Room temperature injectate
Number of subjects: 21
Study: 3773799

Group type: EXPERIMENTAL
Intervention: Vitamin E therapy (300 mg/day intramuscularly for seven days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 41
Study: 2656333

Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide‐5‐mononitrate, orally, three times daily for 4 weeks
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine, orally, three times daily for 4 weeks
Number of subjects: 126

Group type: COMPARATOR
Intervention: 20 mg isosorbide‐5‐mononitrate
Number of subjects: 126

Group type: COMPARATOR
Intervention: 20 mg nifedipine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 126
Study: 31288831

Group type: EXPERIMENTAL
Intervention: Glibenclamide 5 mg daily oral intake for 21 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 80
Study: 28339460

Group type: EXPERIMENTAL
Intervention: IPB only
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: IPB+
Number of subjects: 1112

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1112
Study: 26475792

Group type: EXPERIMENTAL
Intervention: CRYO catheter
Number of subjects: 100

Group type: COMPARATOR
Intervention: VGLA catheter
Number of subjects: 100
Study: 23430672

Group type: EXPERIMENTAL
Intervention: Combined formulation of antioxidants and long-chain EPUFAs (DEDG+S)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DEDG-NS (no supplementation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CG-NS (no supplementation)
Number of subjects: 0
Study: 21934576

Group type: EXPERIMENTAL
Intervention: HPV16-ELISA at manufacturer cut point
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV16-ELISA at optimal cut point
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV18-ELISA at manufacturer cut point
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV18-ELISA at optimal cut point
Number of subjects: 0
Study: 17616556

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once a day
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day
Number of subjects: 458

Group type: COMPARATOR
Intervention: Diclofenac 75 mg twice a day
Number of subjects: 458
Study: 16423738

Group type: EXPERIMENTAL
Intervention: Presentation of a list of semantic associates with omission of one non‐presented word's associates in the second presentation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Presentation of a list of semantic associates without omission (control group).
Number of subjects: 0
Study: 14978780

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 6787

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6787
Study: 10940060

Group type: EXPERIMENTAL
Intervention: Versapulse QS Nd:YAG 532 nm laser
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Versapulse long-pulsed Nd:YAG 532 nm laser
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional QS Nd:YAG 532 nm laser
Number of subjects: 34
Study: 9136264

Group type: EXPERIMENTAL
Intervention: Central foveal scotoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extrafoveal scotoma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no scotoma)
Number of subjects: 0
Study: 8336190

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 294

Group type: COMPARATOR
Intervention: Misonidazole
Number of subjects: 294
Study: 3773581

Group type: EXPERIMENTAL
Intervention: Group practice model
Number of subjects: 302

Group type: COMPARATOR
Intervention: Traditional clinic
Number of subjects: 302
Study: 31215676

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin tablets (875 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral amoxicillin suspension (800 mg)
Number of subjects: 20
Study: 28532232

Group type: EXPERIMENTAL
Intervention: Mixed hydro-alcoholic solution of P. alkekengi, E. amoenum and V. odorata extracts (1.5, 1 and 1.5% respectively)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 86
Study: 25528311

Group type: EXPERIMENTAL
Intervention: Polypill in the evening (aspirin 75 mg, simvastatin 40 mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Polypill in the morning
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Polypill in the evening
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Polypill
Number of subjects: 78
Study: 22538325

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control
Number of subjects: 37
Study: 21617253

Group type: EXPERIMENTAL
Intervention: Microfracturing
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 42
Study: 18357530

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 16946176

Group type: EXPERIMENTAL
Intervention: Lithium augmentation (up to 900 mg/day; N=69)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: T(3) augmentation (up to 50 mug/day; N=73)
Number of subjects: 142
Study: 12580666

Group type: EXPERIMENTAL
Intervention: 3L‐1U group (n = 8) - trained 3 sets in leg exercises and 1 set in upper‐body exercises
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1L‐3U group (n = 10) - trained 1 set in leg exercises and 3 sets in upper‐body exercises
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3L‐1U group
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1L‐3U group
Number of subjects: 18
Study: 11420323

Group type: EXPERIMENTAL
Intervention: Phototherapy (6 hours continuous)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control (6 hours without phototherapy)
Number of subjects: 202
Study: 9285026

Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 22505

Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 22505
Study: 8325280

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 139
Study: 3548793

Group type: EXPERIMENTAL
Intervention: Hyperbaric 0.5% bupivacaine (in 8% glucose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plain 0.5% bupivacaine (glucose-free)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study: 31820605

Group type: EXPERIMENTAL
Intervention: Moxibustion combined with Wenyang Lishui formula
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous infusion of paclitaxel liposome and cisplatin
Number of subjects: 60
Study: 28213595

Group type: EXPERIMENTAL
Intervention: Short Cycle Therapy (SCT) (5 days on: 2 days off)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Continuous efavirenz (EFV)-based antiretroviral therapy (CT)
Number of subjects: 49
Study: 26761970

Group type: EXPERIMENTAL
Intervention: Meldonium (mildronate) during 12 weeks
Number of subjects: 67
Study: 22872429

Group type: EXPERIMENTAL
Intervention: TransInguinal PrePeritoneal (TIPP) repair
Number of subjects: 302

Group type: COMPARATOR
Intervention: Lichtenstein technique
Number of subjects: 302
Study: 21247651

Group type: EXPERIMENTAL
Intervention: 3% solution of tannin rich plant extracts (AS-21) applied topically for 6 weeks
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (glycerol and honey) applied topically for 6 weeks
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 93
Study: 18953197

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 17006078

Group type: EXPERIMENTAL
Intervention: Low thoracic epidural analgesia (group E)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (group P)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 14577817

Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO) based on a modified Zurich approach
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-infant orthopedics (non-IO)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Noncleft controls
Number of subjects: 28
Study: 10755669

Group type: EXPERIMENTAL
Intervention: Individual psychotherapy in combination with antipsychotic medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexible psychotherapy
Number of subjects: 0
Study: 8864420

Group type: EXPERIMENTAL
Intervention: Atropine (5 micrograms kg-1 h-1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg kg-1 h-1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study: 1847977

Group type: COMPARATOR
Intervention: Radiotherapy alone (group A)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and radiotherapy (group B)
Number of subjects: 353
Study: 6679507

Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (1-2 mg/kg; mean dose 86.5 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diazoxide (3-5 mg/kg; mean dose 253.8 mg)
Number of subjects: 13
Study: 30893677

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with tuina (A)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Acupuncture (B)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (flunarizine hydrochloride) (C)
Number of subjects: 135
Study: 28550019

Group type: EXPERIMENTAL
Intervention: Multiple-choice items addressing 22 key concepts
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Rasch analysis
Number of subjects: 1114
Study: 26680752

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training curriculum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 20
Study: 23989030

Group type: EXPERIMENTAL
Intervention: Nia exercise (20-60 minutes, three times per week for 12 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care (continuing normal activities)
Number of subjects: 41
Study: 21288209

Group type: EXPERIMENTAL
Intervention: Pregabalin (75 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 20158046

Group type: EXPERIMENTAL
Intervention: Buccoadhesive tablets of diltiazem hydrochloride (DZH) using HPMC K4M and Carbopol 934
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral tablets of diltiazem hydrochloride
Number of subjects: 0
Study: 17941914

Group type: EXPERIMENTAL
Intervention: Maternal breast-milk containing bifidobacteria
Number of subjects: 61

Group type: COMPARATOR
Intervention: Infants of allergic mothers
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Infants of non-allergic mothers
Number of subjects: 61

Group type: COMPARATOR
Intervention: Breast-milk from allergic mothers
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Breast-milk from non-allergic mothers
Number of subjects: 61
Study: 15492491

Group type: EXPERIMENTAL
Intervention: Higher adherence to early treatment for JCP
Number of subjects: 501

Group type: COMPARATOR
Intervention: Low adherence to early treatment for JCP
Number of subjects: 501
Study: 11851609

Group type: EXPERIMENTAL
Intervention: Contrelle Continence Tampon (CCT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conveen Continence Guard (CCG)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both devices (CCT and CCG)
Number of subjects: 94
Study: 9750978

Group type: EXPERIMENTAL
Intervention: Limited symptom attacks (LSA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infrequent panic (IP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panic disorder (PD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 9001779

Group type: EXPERIMENTAL
Intervention: Gestrinone (Group G)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Buserelin (Group B)
Number of subjects: 43
Study: 2248838

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 7029276

Group type: EXPERIMENTAL
Intervention: Oral propranolol (doses that reduced heart rate by 25%)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 29619796

Group type: EXPERIMENTAL
Intervention: SIT-CHO
Number of subjects: 20

Group type: COMPARATOR
Intervention: SIT-Fast
Number of subjects: 20
Study: 28814086

Group type: EXPERIMENTAL
Intervention: Plasma nesfatin 1 level in patients with first attack psychosis
Number of subjects: 32

Group type: COMPARATOR
Intervention: Plasma nesfatin 1 level in healthy control group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Correlation between plasma nesfatin 1 levels and total PANNS scores in the patient group
Number of subjects: 32
Study: 26886327

Group type: EXPERIMENTAL
Intervention: Cefaclor standard release (SF) 750 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefaclor modified release form (MRF) 750 mg
Number of subjects: 12
Study: 24807748

Group type: EXPERIMENTAL
Intervention: Blind access for PCNL using lumbar notch landmark
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluoroscopy-guided access for PCNL
Number of subjects: 100
Study: 23074432

Group type: EXPERIMENTAL
Intervention: Intensive counselling or a combination of intensive counselling and nicotine replacement therapy (NRT)
Number of subjects: 8291

Group type: COMPARATOR
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 8291

Group type: COMPARATOR
Intervention: Antidepressant bupropion
Number of subjects: 8291
Study: 20605876

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 40
Study: 18049324

Group type: EXPERIMENTAL
Intervention: Music group (n=54)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (n=54)
Number of subjects: 108
Study: 16130056

Group type: EXPERIMENTAL
Intervention: Needle-guided ultrasound (NGU)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Ultrasound without a needle guide
Number of subjects: 429
Study: 11966747

Group type: EXPERIMENTAL
Intervention: SDACTH (250 microg ACTH)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: LDACTH (1 microg ACTH)
Number of subjects: 51

Group type: COMPARATOR
Intervention: OMT (overnight metyrapone test)
Number of subjects: 51
Study: 9863502

Group type: EXPERIMENTAL
Intervention: Dapsone 50 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fansidar one tablet weekly
Number of subjects: 0
Study: 7525635

Group type: EXPERIMENTAL
Intervention: Acute renal failure patients (n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chronic renal failure patients (n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Renal failure patients (both ARF and chronic)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Renal failure patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Renal failure urine samples
Number of subjects: 20
Study: 3301926

Group type: EXPERIMENTAL
Intervention: Topical minoxidil (2% or 3%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Discontinuation of topical minoxidil
Number of subjects: 10
Study: 29435588

Group type: EXPERIMENTAL
Intervention: Type A PCV
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Type B PCV
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Type C PCV
Number of subjects: 61
Study: 26878376

Group type: EXPERIMENTAL
Intervention: Cash incentives group ($150 for confirmed smoking cessation)
Number of subjects: 114

Group type: COMPARATOR
Intervention: No incentive group
Number of subjects: 114
Study: 24417563

Group type: EXPERIMENTAL
Intervention: Peri-implant defect reconstruction with porous titanium granules
Number of subjects: 32

Group type: COMPARATOR
Intervention: Peri-implant defect reconstruction without porous titanium granules (Control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both interventions (irrespective of treatment allocation)
Number of subjects: 32
Study: 22288883

Group type: EXPERIMENTAL
Intervention: Saline irrigation (30 mL/kg) under the diaphragm
Number of subjects: 50

Group type: COMPARATOR
Intervention: No saline irrigation
Number of subjects: 50
Study: 20484099

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg before the intervention and 200 mg twice daily for 6 months)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control (no celecoxib)
Number of subjects: 271
Study: 18777489

Group type: EXPERIMENTAL
Intervention: Muraglitazar 5 mg plus metformin
Number of subjects: 1805

Group type: EXPERIMENTAL
Intervention: Muraglitazar 2.5 mg plus metformin
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Glimepiride 1 mg
Number of subjects: 1805
Study: 16454155

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (Aclasta®), 5 mg infusion
Number of subjects: 357

Group type: COMPARATOR
Intervention: Risedronate (Actonel®), 30 mg/d orally for 2 months
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 357
Study: 12441588

Group type: EXPERIMENTAL
Intervention: Standardized observations by 3 physical therapists and 2 occupational therapists
Number of subjects: 4
Study: 10349786

Group type: EXPERIMENTAL
Intervention: Ulceral (study formula)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Losec (reference standard formula)
Number of subjects: 24
Study: 7813338

Group type: COMPARATOR
Intervention: Pelvic floor repair alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pelvic floor repair with adjuvant internal anal sphincter plication
Number of subjects: 0
Study: 1998019

Group type: EXPERIMENTAL
Intervention: Methyl prednisolone (16 mg in 40 cc saline, concentration 40 mg%)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Gel-saline double-lumen implant with 40 cc saline
Number of subjects: 76
Study: 6359384

Group type: EXPERIMENTAL
Intervention: Amoxycillin (375 mg, three times daily for 7 days)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Cefaclor (250 mg, three times daily for 7 days)
Number of subjects: 139
Study: 31448789

Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin/tazobactam (TZP) 300 mg/kg/day after an initial loading dose of 75 mg/kg over 30 min.
Number of subjects: 176

Group type: COMPARATOR
Intervention: Intermittent infusion of piperacillin/tazobactam (TZP) 300 mg/kg/day divided into four doses, not exceeding 16 g/day.
Number of subjects: 176
Study: 30297911

Group type: EXPERIMENTAL
Intervention: Neoadjuvant ipilimumab 3 mg kg−1 and nivolumab 1 mg kg−1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Adjuvant ipilimumab 3 mg kg−1 and nivolumab 1 mg kg−1
Number of subjects: 20
Study: 27405968

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 19
Study: 24513442

Group type: EXPERIMENTAL
Intervention: Antenatal lifestyle advice (lifestyle advice)
Number of subjects: 2212

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2212
Study: 22036045

Group type: EXPERIMENTAL
Intervention: Ambulatory group
Number of subjects: 130

Group type: COMPARATOR
Intervention: Non-ambulatory group
Number of subjects: 130
Study: 20680859

Group type: EXPERIMENTAL
Intervention: Medicine companions (MCs) chosen by participants for ART adherence support
Number of subjects: 1453

Group type: EXPERIMENTAL
Intervention: Qualitative interviews regarding the experience with MCs
Number of subjects: 1453

Group type: EXPERIMENTAL
Intervention: Participants who disclosed their serostatus
Number of subjects: 1453

Group type: EXPERIMENTAL
Intervention: General experience with MCs
Number of subjects: 1453
Study: 18203070

Group type: EXPERIMENTAL
Intervention: Extended Daily Dialysis with filtration (EDDf)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continuous Veno‐Venous Hemofiltration (CVVH)
Number of subjects: 16
Study: 15557391

Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 IU/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 80
Study: 12468775

Group type: EXPERIMENTAL
Intervention: ZK200775 (dose group 2: 525 mg in 48 hours)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ZK200775 (dose group 1: 262.5 mg in 48 hours)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ZK200775 (dose group 3: 105 mg over 6 hours)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 9812120

Group type: EXPERIMENTAL
Intervention: Fluoxetine 10 mg/day
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243